Now in Cancer Discovery @aacrjournals.bsky.social: Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators - by @ferranfececruz.bsky.social, Andreas Varkaris, Aparna Parikh, Ryan Corcoran, et al. doi.org/10.1158/2159... @mgbresearch.bsky.social @harvardmed.bsky.social

Acquired on-target alterations drive clinical resistance to p53-Y220C reactivators aacrjournals.org/cancerdiscov...

Happy to report the first clinical evidence revealing how tumors develop resistance to p53-Y220C reactivators out today at Cancer Discovery @aacrjournals.bsky.social @mgbresearch.bsky.social @harvardmed.bsky.social @oncoalert.bsky.social @oncodaily.bsky.social #CorcoranLab #Rezatapopt #PYNNACLE

💯

⚠️ #CorcoranLab reports "Genomic landscape of clinically acquired resistance alterations in patients treated with #KRASG12C inhibitors", a work led by our brilliant Austrian postdoc Jakob Riedl! @mgbresearch.bsky.social @fwf-at.bsky.social @harvardmed.bsky.social @oncoalert.bsky.social #crcsm #lcsm

I give up 🤦🏻‍♂️ #TheHandmaidsTale

Pan-RAS inhibitor RMC-6236 aka Daraxonrasib in patients with RAS-mutant pancreatic adenocarcinoma 🤯🤯🤯 #GI25 dailynews.ascopubs.org/do/pan-ras-i...

Phase 3 #BREAKWATER trial demonstrate a significantly improved response rate that was durable for first-line Encorafenib + Cetuximab + mFOLFOX6 vs. SOC in patients with BRAF V600E mCRC #crcsm #BRAF #GI25 @fightcrc.bsky.social www.nature.com/articles/s41...

🤯🤯🤯

Incidence and characterization of TOP1 mutations arising in the setting of ADC resistance in metastatic breast cancer, and the potential impact on mediating cross-resistance to sequential ADCs! @harvardmed.bsky.social @breastcancernow.bsky.social #CorcoranLab #bcsm #biomarkers #resistance

Great news! #RAS

😢

Living the targeting #RAS era 🤯🤯🤯 #KRAS #G12C #G12D www.cell.com/trends/cance...

Safety and efficacy of the next generation of PI3K targeting agents reviewed @sabcs.bsky.social #SABCS24 poster highlights PS7-01-02-03 @oncoalert.bsky.social

Great news fresh from #SABCS24 RLY-2608 (mutant selective PI3Kα inhibitor): mPFS 9.2m (all patients) mPFS 11.4m (for kinase domain mutants H1047R) Clinical Benefit Rate 67% #bcsm @breastcancernow.bsky.social

"Thirty years after the sequencing of the BRCA1 cancer-associated gene, access to genetic tests and awareness about its risks are still too limited."

Interesting perspective on key considerations for sponsors and investigators pursuing dose optimization with combinatorial regimens @oncoalert.bsky.social #CancerTherapeutics #DrugDevelopment #Synergy

Durvalumab now FDA approved for limited stage #SCLC based on the phase III ADRIATIC trial showing a PFS and an OS benefit (HR 0.73) with 2y of durvalumab after completion of definitive chemoradiation (avoid concurrent use). #LCSM #OncSky www.targetedonc.com/view/durvalu....

"Although the policies of the incoming administration are not yet unsettled, fears and uncertainties can wreak damage on student morale. Check in with the foreign students/fellows in your classes, labs, and institutions." @harvardmed.bsky.social @aclum.bsky.social @academic-chatter.bsky.social

💪🏼💪🏼💪🏼 elpais.com/economia/neg...

🔬🧪🧫💪🏼 catalonia.com/w/barcelona-...

⬇️⬇️⬇️

Ryan Corcoran, MD, PhD, and Aparna Parikh, MD, answer questions about the science behind blood testing to check for remaining cancer cells after surgery #LiquidBiopsy #MRD www.massgeneralbrigham.org/en/about/new...

💪🏼💪🏼💪🏼

Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer 🤯🤯🤯 #crcsm #NEJM ⬇️⬇️⬇️ www.nejm.org/doi/full/10....

Hello Bluesky!

Great news for HR+/HER2- metastatic breast cancer patients! #INAVO120 #bcsm @breastcancernow.bsky.social #NEJM Next, mutant-selective PIK3CA inhibitors... ⬇️⬇️⬇️ www.nejm.org/doi/full/10....